{
    "download_date": [
        "ClinicalTrials.gov processed this data on May 09, 2023"
    ],
    "link_text": [
        "Link to the current ClinicalTrials.gov record."
    ],
    "url": [
        "https://clinicaltrials.gov/show/NCT05482568"
    ],
    "org_study_id": [
        "SHR-A1811-II-203"
    ],
    "nct_id": [
        "NCT05482568"
    ],
    "brief_title": [
        "A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer"
    ],
    "official_title": [
        "Phase IB/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer With HER2"
    ],
    "lead_sponsor": [],
    "source": [
        "Jiangsu HengRui Medicine Co., Ltd."
    ],
    "is_fda_regulated_drug": [
        "No"
    ],
    "is_fda_regulated_device": [
        "No"
    ],
    "textblock": [
        "This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical\r\n      trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in\r\n      subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two\r\n      parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined\r\n      with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811\r\n      combined with SHR-1316."
    ],
    "overall_status": [
        "Not yet recruiting"
    ],
    "type": [
        "Anticipated",
        "Anticipated",
        "Anticipated",
        "Anticipated",
        "Actual",
        "Actual"
    ],
    "start_date": [
        "August 20, 2022"
    ],
    "completion_date": [
        "December 30, 2024"
    ],
    "primary_completion_date": [
        "November 30, 2023"
    ],
    "phase": [
        "Phase 1/Phase 2"
    ],
    "study_type": [
        "Interventional"
    ],
    "has_expanded_access": [
        "No"
    ],
    "allocation": [],
    "intervention_model": [
        "Single Group Assignment"
    ],
    "intervention_model_description": [
        "An open, multicenter, dose-increasing/investigational Phase IB/II clinical trial"
    ],
    "primary_purpose": [
        "Treatment"
    ],
    "masking": [
        "None (Open Label)"
    ],
    "measure": [
        "DLT(Phase I (dose exploration phase) main study endpoint)",
        "AE(Phase I (dose exploration phase) main study endpoint)",
        "Incidence and severity of serious adverse events (SAE)(Phase I (dose exploration phase) main study endpoint)",
        "Objective response rate(The main end points of the second stage (efficacy expansion stage))",
        "Toxin binding antibody to shr-a1811\uff08Phase I secondary endpoint\uff09",
        "Total antibody to shr-a1811\uff08Phase I secondary endpoint\uff09",
        "Plasma concentration of free toxin shr169265\uff08Phase I secondary endpoint\uff09",
        "Plasma concentration of pyrroltinib\uff08Phase I secondary endpoint\uff09",
        "Plasma concentration of SHR-1316\uff08Phase I secondary endpoint\uff09",
        "Anti shr-a1811 antibody positive\uff08Phase I secondary endpoint\uff09",
        "The positive status of neutralizing antibody against shr-a1811\uff08Phase I secondary endpoint\uff09",
        "Anti shr-1316 antibody positive\uff08Phase I secondary endpoint\uff09",
        "The positive status of neutralizing antibody against shr-1316\uff08Phase I secondary endpoint\uff09",
        "Objective Response Rate\uff08Phase I secondary endpoint\uff09",
        "Duration of response\uff08Phase I secondary endpoint\uff09",
        "Progression Free Survival\uff08Phase I secondary endpoint\uff09",
        "AE\uff08Phase II secondary study endpoint\uff09",
        "Incidence and severity of serious adverse events (SAE)\uff08Phase II secondary study endpoint\uff09",
        "Toxin binding antibody to shr-a1811\uff08Phase II secondary study endpoint\uff09",
        "Total antibody to shr-a1811\uff08Phase II secondary study endpoint\uff09",
        "Plasma concentration of free toxin shr169265\uff08Phase II secondary study endpoint\uff09",
        "Plasma concentration of pyrroltinib\uff08Phase II secondary study endpoint\uff09",
        "Plasma concentration of SHR-1316\uff08Phase II secondary study endpoint\uff09",
        "Anti shr-a1811 antibody positive\uff08Phase II secondary study endpoint\uff09",
        "The positive status of neutralizing antibody against shr-a1811\uff08Phase II secondary study endpoint\uff09",
        "Anti shr-1316 antibody positive\uff08Phase II secondary study endpoint\uff09",
        "The positive status of neutralizing antibody against shr-1316\uff08Phase II secondary study endpoint\uff09",
        "Duration of response\uff08Phase II secondary study endpoint\uff09",
        "Progression Free Survival\uff08Phase II secondary study endpoint\uff09"
    ],
    "time_frame": [
        "21 days after the first administration of each subject",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group",
        "Two years after the last subject was enrolled in the group"
    ],
    "number_of_arms": [
        1.0
    ],
    "enrollment": [
        324.0
    ],
    "condition": [
        "Advanced Non-small Cell Lung Cancer"
    ],
    "arm_group_label": [
        "SHR-A1811 combined with Pyrotinib/SHR-A1811 combined with SHR-1316",
        "SHR-A1811 combined with Pyrotinib/SHR-A1811 combined with SHR-1316"
    ],
    "arm_group_type": [
        "Experimental"
    ],
    "intervention_type": [
        "Drug"
    ],
    "intervention_name": [
        "SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316"
    ],
    "description": [
        "Drug: SHR-A1811 & Pyrotinib\r\nSHR-A1811\uff1a intravenous Pyrotinib\uff1aoral\r\nDrug: SHR-A1811 & SHR-1316\r\nSHR-A1811\uff1a intravenous SHR-1316\uff1a intravenous"
    ],
    "criteria": [],
    "gender": [
        "All"
    ],
    "minimum_age": [
        "18 Years"
    ],
    "maximum_age": [
        "75 Years"
    ],
    "healthy_volunteers": [
        "No"
    ],
    "last_name": [
        "Suqiang Yu"
    ],
    "phone": [
        "+0518-82342973"
    ],
    "email": [
        "suqiang.yu@hengrui.com"
    ],
    "verification_date": [
        "July 2022"
    ],
    "study_first_submitted": [
        "July 26, 2022"
    ],
    "study_first_submitted_qc": [
        "July 29, 2022"
    ],
    "study_first_posted": [
        "August 1, 2022"
    ],
    "last_update_submitted": [
        "July 29, 2022"
    ],
    "last_update_submitted_qc": [
        "July 29, 2022"
    ],
    "last_update_posted": [
        "August 1, 2022"
    ],
    "responsible_party_type": [
        "Sponsor"
    ],
    "mesh_term": [
        "Carcinoma, Non-Small-Cell Lung"
    ],
    "sharing_ipd": [
        "Undecided"
    ]
}